<table id="table11" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 11: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [See<linkhtml href="#S12.3"> Clinical Pharmacology (12.3) </linkhtml>for Magnitude of Interaction, <linkhtml href="#table14">Tables 14</linkhtml> and <linkhtml href="#table15">15</linkhtml>]</caption>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="45%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule" valign="bottom">Concomitant Drug Class:<br/>Drug Name</th>
<th align="center" stylecode="Rrule">Effect on Concentration of Darunavir or Concomitant Drug</th>
<th align="center" stylecode="Rrule" valign="bottom">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1-Antiviral Agents: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">didanosine</td>
<td stylecode="Rrule">↔ darunavir<br/>↔ didanosine</td>
<td stylecode="Rrule">Didanosine should be administered one hour before or two hours after PREZISTA/ritonavir (which are administered with food).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1-Antiviral Agents: HIV-Protease Inhibitors (PIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">indinavir<br/> <br/>(The reference regimen for indinavir was indinavir/ritonavir 800/100 mg twice daily.)</td>
<td stylecode="Rrule">↑ darunavir<br/>↑ indinavir</td>
<td stylecode="Rrule">The appropriate dose of indinavir in combination with PREZISTA/ritonavir has not been established.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">lopinavir/ritonavir</td>
<td stylecode="Rrule">↓ darunavir<br/>↔ lopinavir</td>
<td stylecode="Rrule">Appropriate doses of the combination have not been established. Hence, it is not recommended to co-administer lopinavir/ritonavir and PREZISTA, with or without ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">saquinavir</td>
<td stylecode="Rrule">↓ darunavir<br/>↔ saquinavir</td>
<td stylecode="Rrule">Appropriate doses of the combination have not been established. Hence, it is not recommended to co-administer saquinavir and PREZISTA, with or without ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1-Antiviral Agents: CCR5 co-receptor antagonists</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">maraviroc</td>
<td stylecode="Rrule">↑ maraviroc</td>
<td stylecode="Rrule">When used in combination with PREZISTA/ritonavir, the dose of maraviroc should be 150 mg twice daily.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antiarrhythmics</content>:<br/>e.g.<br/>amiodarone,<br/>bepridil,<br/>disopyramide,<br/>flecainide,<br/>lidocaine (systemic),<br/>mexiletine,<br/>propafenone,<br/>quinidine,</td>
<td stylecode="Rrule">↑ antiarrhythmics</td>
<td stylecode="Rrule">Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">digoxin</td>
<td stylecode="Rrule">↑ digoxin</td>
<td stylecode="Rrule">The lowest dose of digoxin should initially be prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antibacterial</content>:<br/>clarithromycin</td>
<td stylecode="Rrule">↔ darunavir<br/>↑ clarithromycin</td>
<td stylecode="Rrule">No dose adjustment of the combination is required for patients with normal renal function. For co-administration of clarithromycin and PREZISTA/ritonavir in patients with renal impairment, the following dose adjustments should be considered: 									<list listtype="unordered" stylecode="disc">
<item>For subjects with CLcr of 30–60 mL/min, the dose of clarithromycin should be reduced by 50%.</item>
<item>For subjects with CLcr of &lt;30 mL/min, the dose of clarithromycin should be reduced by 75%.</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulant</content>:<br/>apixaban,<br/>dabigatran etexilate,</td>
<td stylecode="Rrule">↑ anticoagulant</td>
<td stylecode="Rrule">Concomitant use of apixaban and PREZISTA/ritonavir is not recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">The combination of PREZISTA/ritonavir and dabigatran etexilate is not recommended in specific renal impairment groups, depending on the indication. Please see the dabigatran U.S. prescribing information for specific recommendations.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">rivaroxaban</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Co-administration of PREZISTA/ritonavir and rivaroxaban is not recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">↓ warfarin</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">warfarin</td>
<td stylecode="Rrule">↔ darunavir</td>
<td stylecode="Rrule">Warfarin concentrations are decreased when co-administered with PREZISTA/ritonavir. It is recommended that the international normalized ratio (INR) be monitored when warfarin is combined with PREZISTA/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsant</content>:<br/>carbamazepine</td>
<td stylecode="Rrule">↔ darunavir<br/>↑ carbamazepine</td>
<td stylecode="Rrule">The dose of either darunavir/ritonavir or carbamazepine does not need to be adjusted when initiating co-administration with darunavir/ritonavir and carbamazepine. Clinical monitoring of carbamazepine concentrations and its dose titration is recommended to achieve the desired clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsant</content>:<br/>phenobarbital,<br/>phenytoin</td>
<td stylecode="Rrule">↔ darunavir<br/>↓ phenytoin<br/>↓ phenobarbital</td>
<td stylecode="Rrule">Phenytoin and phenobarbital levels should be monitored when co-administering with PREZISTA/ritonavir.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antidepressant</content>:<br/>Selective Serotonin Reuptake Inhibitors (SSRIs):<br/>paroxetine,<br/>sertraline</td>
<td stylecode="Rrule">↓ paroxetine<br/>↓ sertraline</td>
<td stylecode="Rrule">If either sertraline or paroxetine is initiated in patients receiving PREZISTA/ritonavir, dose titrating the SSRI based on a clinical assessment of antidepressant response is recommended. Monitor for antidepressant response in patients on a stable dose of sertraline or paroxetine who start treatment with PREZISTA/ritonavir.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Tricyclic Antidepressants (TCAs):<br/>amitriptyline,<br/>desipramine<br/>imipramine,<br/>nortriptyline</td>
<td stylecode="Rrule">↑ amitriptyline<br/>↑ desipramine<br/>↑ imipramine<br/>↑ nortriptyline</td>
<td stylecode="Rrule">Use a lower dose of the tricyclic antidepressants and trazodone due to potential increased adverse events such as nausea, dizziness, hypotension and syncope.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Other:<br/>trazodone</td>
<td stylecode="Rrule">↑trazodone</td>
<td stylecode="Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungals</content>:<br/>itraconazole,<br/>ketoconazole,<br/>posaconazole<br/>
<br/>voriconazole</td>
<td stylecode="Rrule">↑ darunavir<br/>↑ itraconazole<br/>(not studied)<br/>↑ ketoconazole<br/>↔ posaconazole (not studied)</td>
<td stylecode="Rrule">Monitor for increased PREZISTA/ritonavir adverse events with concomitant use of itraconazole, ketoconazole, or posaconazole. When co-administration is required, the daily dose of ketoconazole or itraconazole should not exceed 200 mg with monitoring for increased antifungal adverse events.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">↓ voriconazole<br/>(not studied)</td>
<td stylecode="Rrule">Voriconazole is not recommended for patients receiving darunavir/ritonavir unless an assessment comparing predicted benefit to risk ratio justifies the use of voriconazole.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-gout</content>:<br/>colchicine</td>
<td stylecode="Rrule">↑ colchicine</td>
<td stylecode="Rrule">
<content stylecode="underline">Treatment of gout-flares – co-administration of colchicine in patients on PREZISTA/ritonavir:</content>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days.<br/> <br/>
<paragraph>
<content stylecode="underline">Prophylaxis of gout-flares – co-administration of colchicine in patients on PREZISTA/ritonavir:</content>
<br/>If the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>If the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day. </paragraph>
<br/>
<paragraph>
<content stylecode="underline">Treatment of familial Mediterranean fever – co-administration of colchicine in patients on PREZISTA/ritonavir:</content>
<br/>maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).<br/>Co-administration of PREZISTA/ritonavir with colchicine in patients with renal or hepatic impairment is CONTRAINDICATED.</paragraph>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimalarials</content>:<br/>artemether/lumefantrine</td>
<td stylecode="Rrule">↓ artemether<br/>↓ dihydroartemisinin<br/>↑ lumefantrine<br/>↔ darunavir</td>
<td stylecode="Rrule">The combination of PREZISTA/ritonavir and artemether/lumefantrine can be used without dose adjustments. However, the combination should be used with caution as increased lumefantrine exposure may increase the risk of QT prolongation.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterial</content>:<br/>rifabutin</td>
<td rowspan="2" stylecode="Rrule">↑ darunavir<br/>↑ rifabutin<br/>↑ 25-<content stylecode="italics">O</content>-desacetylrifabutin</td>
<td rowspan="2" stylecode="Rrule">Dose reduction of rifabutin by at least 75% of the usual dose (300 mg once daily) is recommended (i.e., a maximum dose of 150 mg every other day). Increased monitoring for adverse events is warranted in patients receiving this combination and further dose reduction of rifabutin may be necessary.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">The reference regimen for rifabutin was 300 mg once daily</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">rifapentine</td>
<td stylecode="Rrule">↓ darunavir</td>
<td stylecode="Rrule">Co-administration of PREZISTA/ritonavir with rifapentine is not recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antineoplastics:</content>
<br/>dasatinib<br/>nilotinib<br/>vinblastine<br/>vincristine</td>
<td stylecode="Rrule">↑Antineoplastics</td>
<td stylecode="Rrule">A decrease in the dosage or an adjustment of the dosing interval of dasatinib and nilotinib may be necessary for patients.  Please refer to the dasatinib and nilotinib U.S. prescribing information for dosing instructions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">For vincristine and vinblastine, consideration should be given to temporarily withholding the ritonavir-containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when PREZISTA/ritonavir is administered concurrently with vincristine or vinblastine. If the antiretroviral regimen must be withheld for a prolonged period, consideration should be given to initiating a revised regimen that does not include a CYP3A or P-gp inhibitor. </td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antipsychotics</content>:<br/>quetiapine</td>
<td stylecode="Rrule">↑ quetiapine</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of PREZISTA with ritonavir in patients taking quetiapine:</content>
<br/>Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If co-administration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine U.S. prescribing information for recommendations on adverse reaction monitoring. <br/> <br/>
<content stylecode="underline">Initiation of quetiapine in patients taking PREZISTA with ritonavir:</content>
<br/>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">e.g.<br/>risperidone,<br/>thioridazine</td>
<td stylecode="Rrule">↑ antipsychotics</td>
<td stylecode="Rrule">A dose decrease may be needed for these drugs when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">β-Blockers</content>:<br/>e.g.<br/>carvedilol,<br/>metoprolol,<br/>timolol</td>
<td stylecode="Rrule">↑ beta-blockers</td>
<td stylecode="Rrule">Clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PREZISTA/ritonavir and a lower dose of the beta blocker should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium Channel Blockers</content>:<br/>amlodipine,<br/>diltiazem,<br/>felodipine,<br/>nicardipine<br/>nifedipine,<br/>verapamil</td>
<td stylecode="Rrule">↑ calcium channel blockers </td>
<td stylecode="Rrule">Clinical monitoring of patients is recommended.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid (systemic)</content>:<br/>dexamethasone</td>
<td stylecode="Rrule">↓ darunavir</td>
<td stylecode="Rrule">Systemic dexamethasone induces CYP3A and can thereby decrease darunavir plasma concentrations. This may result in loss of therapeutic effect to PREZISTA.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid (systemic):</content>
<br/>metabolized by CYP3A</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">e.g.<br/>budesonide<br/>prednisolone</td>
<td stylecode="Rrule">↑ corticosteroid</td>
<td stylecode="Rrule">Concomitant use of corticosteroids metabolized by CYP3A may increase the risk for development of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Alternatives should be considered, particularly for long-term use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid (inhaled/nasal)</content>:<br/>budesonide,<br/>fluticasone</td>
<td stylecode="Rrule">↑ corticosteroid</td>
<td stylecode="Rrule">Alternatives should be considered, particularly for long-term use.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Endothelin receptor antagonists</content>:<br/>bosentan</td>
<td stylecode="Rrule">↑ bosentan</td>
<td stylecode="Rrule">
<paragraph>
<content stylecode="underline">Co-administration of bosentan in patients on PREZISTA/ritonavir:</content>
<br/>In patients who have been receiving PREZISTA/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability. </paragraph>
<br/>
<paragraph>
<content stylecode="underline">Co-administration of PREZISTA/ritonavir in patients on bosentan:</content>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of PREZISTA/ritonavir. After at least 10 days following the initiation of PREZISTA/ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hepatitis C Virus (HCV) Direct-Acting Agents: <br/>NS3-4A protease inhibitors:</content>
<br/>boceprevir<br/>telaprevir</td>
<td stylecode="Rrule">↓ darunavir <br/>↓ boceprevir<br/>↓ telaprevir</td>
<td stylecode="Rrule">
<paragraph>Co-administration of boceprevir or telaprevir and PREZISTA/ritonavir is not recommended.</paragraph>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">simeprevir</td>
<td stylecode="Rrule" valign="bottom">↑ simeprevir<br/>↑ darunavir</td>
<td stylecode="Rrule" valign="middle">Co-administration of darunavir/ritonavir and simeprevir is not recommended</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA</content>
<br/>
<content stylecode="bold">Reductase Inhibitors</content>:<br/>atorvastatin,<br/>pravastatin,<br/>rosuvastatin</td>
<td stylecode="Rrule">↑ HMG-CoA Reductase Inhibitors</td>
<td stylecode="Rrule">Co-administration of PREZISTA/ritonavir with HMG-Co A reductase inhibitors may lead to adverse events such as myopathy. Titrate atorvastatin, pravastatin or rosuvastatin dose carefully and use the lowest necessary dose while monitoring for adverse events.  Do not exceed atorvastatin  20 mg/day.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressants</content>:<br/>e.g.<br/>cyclosporine,<br/>tacrolimus,<br/>sirolimus</td>
<td stylecode="Rrule">↑ immunosuppressants</td>
<td stylecode="Rrule">Therapeutic concentration monitoring of the immunosuppressive agent is recommended when co-administered with PREZISTA/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressants/neoplastic:</content>
<br/>everolimus</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule" valign="bottom">Co-administration of everolimus and PREZISTA/ritonavir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled beta agonist</content>:<br/>salmeterol</td>
<td stylecode="Rrule">↑ salmeterol</td>
<td stylecode="Rrule">Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesic/Treatment of Opioid Dependence</content>:<br/>buprenorphine,<br/>buprenorphine/naloxone,<br/>methadone</td>
<td stylecode="Rrule">↔  buprenorphine, naloxone<br/>↑ norbuprenorphine (metabolite)<br/>↓ methadone</td>
<td stylecode="Rrule">No adjustment of methadone dosage is required when initiating co-administration of PREZISTA/ritonavir. However, clinical monitoring is recommended as the dose of methadone during maintenance therapy may need to be adjusted in some patients.<br/>No dose adjustment for buprenorphine or buprenorphine/naloxone is required with concurrent administration of PREZISTA/ritonavir. Clinical monitoring is recommended if PREZISTA/ritonavir and buprenorphine or buprenorphine/naloxone are coadministered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Oral Contraceptives/estrogen</content>:<br/>ethinyl estradiol,<br/>norethindrone</td>
<td stylecode="Rrule">↓ ethinyl estradiol<br/>↓ norethindrone</td>
<td stylecode="Rrule">Alternative methods of nonhormonal contraception are recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">PDE-5 inhibitors</content>:<br/>e.g.<br/>avanafil,<br/>sildenafil,<br/>tadalafil,<br/>vardenafil</td>
<td stylecode="Rrule">↑ PDE-5 inhibitors (only the use of sildenafil at doses used for treatment of erectile dysfunction has been studied with PREZISTA/ritonavir)</td>
<td stylecode="Rrule">
<paragraph>Co-administration with PREZISTA/ritonavir may result in an increase in PDE-5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances and priapism.</paragraph>
<br/>
<paragraph>
<content stylecode="underline">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</content>
</paragraph>
<list>
<item>Use of sildenafil is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) [<content stylecode="italics">see <linkhtml href="#S4">Contraindications (4)</linkhtml>
</content>].</item>
<item>The following dose adjustments are recommended for use of tadalafil with PREZISTA/ritonavir:<br/>
<content stylecode="underline">Co-administration of tadalafil in patients on PREZISTA/ritonavir:</content>
<br/>In patients receiving PREZISTA/ritonavir for at least one week, start tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<content stylecode="underline">Co-administration of PREZISTA/ritonavir in patients on tadalafil:</content>
<br/>Avoid use of tadalafil during the initiation of PREZISTA/ritonavir. Stop tadalafil at least 24 hours prior to starting PREZISTA/ritonavir. After at least one week following the initiation of PREZISTA/ritonavir, resume tadalafil at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability. </item>
</list>
<paragraph>
<content stylecode="underline">Use of PDE-5 inhibitors for erectile dysfunction:</content>
<br/>Sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg dose in 72 hours, or tadalafil at a single dose not exceeding 10 mg dose in 72 hours can be used with increased monitoring for PDE-5 inhibitor-associated adverse events. </paragraph>
<paragraph>Co-administration of PREZISTA/ritonavir and avanafil is not recommended.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Sedatives/Hypnotics:</content>
<br/>Metabolized by CYP3A<br/>e.g.<br/>buspirone,<br/>diazepam,<br/>estazolam,<br/>parenterally administered midazolam,<br/>zoldipem</td>
<td stylecode="Rrule">↑ sedatives/hypnotics</td>
<td stylecode="Rrule">
<paragraph>Titration is recommended when co-administering PREZISTA/ritonavir with sedatives/hypnotics metabolized by CYP3A and a lower dose of the sedatives/hypnotics should be considered with monitoring for adverse events.</paragraph>
<paragraph>Co-administration of parenteral midazolam should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Co-administration of oral midazolam or triazolam with PREZISTA/ritonavir is CONTRAINDICATED.</paragraph>
</td>
</tr>
</tbody>
</table>